Risk factors associated with multiple-species candidemia;Factores de riesgo asociados a candidemias causadas por múltiples especies

Revista Argentina de Microbiologia

Volumn 40, Issue 1, 2008, Pages 30-36

  Benetucci, A ^a   Tiraboschi, I N ^a   Fernandez N ^a   Perazzi, B ^a   Lasala, M B ^a  

^a HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

Author keywords

Candidemia; Fungemia; Multiple species candidemia

Indexed keywords

ADULT; AGED; ARGENTINA; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA PARAPSILOSIS; CANDIDA PELLICULOSA; CANDIDA TROPICALIS; CANDIDIASIS; CATHETER INFECTION; CENTRAL VENOUS CATHETER; CLINICAL ARTICLE; DISEASE DURATION; FEMALE; HOSPITALIZATION; HUMAN; INFECTION RISK; LENGTH OF STAY; MALE; NEWBORN; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CANDIDA; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; FEMALE; FUNGEMIA; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; RISK FACTORS;

EID: 44349187935     PISSN: 03257541     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Ahmad S, Khan Z, Mustafa AS, Khan ZU. Seminested PCR for diagnosis of candidemia: comparison with culture, antigen detection, and biochemical methods for species identification. J Clin Microbiol 2002; 40: 2483-9.
2. Almirante B, Rodríguez D, Park BJ, Cuenca-Estrella M, Planes AM, Almela M, et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005; 43: 1829-35.
3. Anaissie EJ, Rex JH, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 1998; 104: 238-45.
4. Antoniadou A, Torres HA, Russell EL, Thornby J, Bodey GP, Tarrand JJ, et al. Candidemia in a tertiary care center. In vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine 2003; 82: 309-21.
5. Beck-Sagué CM, Jarvis WR, and the National Nosocomial Infections Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993; 167: 1257-61.
6. Ben-Abraham R, Keller N, Todorvitch N, Barzilai A, Harel R, Barzilay Z, et al. Predictors of adverse outcome from candidal infection in a tertiary care hospital. J Infect 2004; 49: 317-23.
7. Bertagnolio S, De Gaetano Donati K, Tacconelli E, Scoppettuolo G, Posteraro B, Fadda G, et al. Hospital-acquired candidemia in HIV-infected patients: incidence, risk factors and predictors of outcome. J Chemother 2004; 16: 172-8.
8. Bodey GP, Mardani M, Hanna HA, Boktour M, Abbas J, Girgawy E, et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 2002; 112: 380-5.
9. Boktour MH, Kontoyiannis DP, Hanna HA, Hachem RY, Girgawy E, Bodey GP, et al. Multiple-species candidemia in patients with cancer. Cancer 2004; 101: 1860-5.
10. Bross J, George HT, Maislin G, Hurwitz S, Strom BL. Risk factors for nosocomial candidemia: a case-control study in adults without leukemia. Am J Med 1989; 87: 614-20.
11. Charles PE, Doise JM, Quenot JP, Aube H, Dalle F, Chavanet P, et al. Candidemia in critically ill patients: difference of outcome between medical and surgical patients. Intensive Care Med 2003; 29: 2162-9.
12. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999; 29: 239-44.
13. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992; 15: 414-21.
14. Fridman D, Tiraboschi IN, Valenzuela MV, Lasala MB. Estudio comparativo de medios de cultivo para la identificación de Candida albicans. Rev Arg Micol 1996; 19: 18-20.
15. Garbino J, Kolarova L, Rohner P, Lew D, Pichna P, Pittet D. Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital. Medicine 2002; 81: 425-33.
16. Goodrich JM, Reed EC, Mori M, Fisher LD, Skerrett S, Dandliker PS, et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 1991; 164: 731-40.
17. Gottfredsson M, Vredenburgh JJ, Xu J, Schell WA, Perfect JR. Candidemia in women with breast carcinoma treated with high-dose chemotherapy and autologous bone marrow transplantation. Cancer 2003; 98: 24-30.
18. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-7.
19. Guerra-Romero T, Telenti A, Thompson RL, Roberts GD. Polymicrobial fungemia: microbiology, clinical features, and significance. Rev Infect Dis 1989; 11: 208-12.
20. Harvey RL, Myers JP. Nosocomial fungemia in a large community teaching hospital. Arch Intern Med, 1987; 147: 2117-20.
21. nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2002, abstract M-881, p. 391, San Diego, CA.
22. Kontoyiannis DP, Vaziri I, Hanna HA, Boktour M, Thornby J, Hachem R, et al. Risk factors for Candida tropicalis fungemia in patients with cancer. Clin Inf Dis 2001; 33: 1676-81.
23. Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, et al. Epidemiology of candidemia in swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004; 38: 311-20.
24. Marr KA, Sidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181: 309-16.
25. Michalopoulos AS, Geroulanos S, Mentzelopoulos SD. Determinants of candidemia-related death in cardiothoracic ICU patients. Chest 2003; 124: 2244-55.
26. Nguyen MH, Peacock JE, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996; 100: 617-23.
27. Nolla-Salas J, Stiges-Serra A, Leon-Gil C, Martínez- González J, León-Regidor MA, Ibáñez-Lucía P, et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Intensive Care Med 1997; 23: 23-30.
28. Ostrosky-Zeichner L. New aproaches to the risk of Candida in the intensive care unit. Curr Opin Infect Dis 2003; 16: 533-7.
29. Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: 634-43.
30. Pemán J, Cantón E, Orero A, Viudes A, Frasquet J, Gobernado M y los participantes españoles del estudio multicéntrico Epidemiological Survey of Candidemia in Europe. Estudio multicéntrico sobre epidemiología de las candi-demias en España. Rev Iberoam Micol 2002; 19: 30-5.
31. Pfaller MA, Diekema DJ, Rinaldi M, Barnes R, Bijie H, Veselov A, Tiraboschi N, Nagy E, Gibbs DL and the Global Antifungal Surveillance Group. Results from the ARTEMIS DISK global antifungal surveillance study: a 6.5 year analysis of the worlwide susceptibility of yeasts to fluconazole and voriconazole using standardized disk diffusion testing. J Clin Microbiol 2005; 43: 5848-59.
32. Poikonen E, Lyytikäinen O, Anttila VJ, Ruutu P. Candidemia in Finland, 1995-1999. Emerg Infect Dis 2003; 9: 985-90.
33. Pulimood S, Ganesan L, Alangaden G, Chandrasekar P. Polymicrobial candidemia. Diagn Microbiol Infect Dis 2002; 44: 353-7.
34. Safdar A, Bannister TW, Safdar Z. The predictors of outcome in immunocompetent patients with hematogenous candidiasis. Int J Infect Dis 2004; 8: 180-6.
35. Safdar A, Cross EW, Chaturredi V, Perlin DS, Armstrong D. Prolonged candidemia in patients with cancer. Clin Infect Dis 2002; 35: 778-9.
36. Safdar A, van Rhee F, Henslee-Downey JP, Singhal S, Mehta J. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplant 2001; 28: 873-8.
37. Shetty SS, Harrison LH, Hajjeh RA, Taylor T, Mirza SA, Bustamante Schmidt A, et al. Determining risk factors for candidemia among newborn infants from population-based surveillance. Pediatr Infect Dis J 2005; 24: 601-4.
38. Snydman DR. Shifting patterns in the epidemiology of nosocomial Candida infections. Chest 2003; 123: 500-3.
39. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP, and the National Nosocomial Infectious Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002; 35: 627-30.
40. Viscoli C, Girmenia C, Marinus A, Collette L, Martino P, Vandercam B, et al. Candidemia in cancer patients. A prospective, multicenter surveillance study by the invasive fungal infection group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28: 1071-9.
41. Zaoutis TE, Greves M, Lautenbach E, Bilker WB, Coffin SE. Risk factors for disseminated candidiasis in children with candidemia. Pediatr Infect Dis J 2004; 23: 635-41.